KRAS G12C
13
5
8
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (13)
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
JDQ443 for KRAS G12C NSCLC Brain Metastases